Newly Published Chronic Heart Failure Treatment Study Provides Promising Results for EVBA Procedure with Unique MobiusHD Device

Vascular Dynamics, Inc. (VDI), a privately held medical device company focused on developing game-changing endovascular device-based solutions for patients suffering from heart failure, announced that a study assessing its MobiusHD device to treat patients with chronic heart failure has been published in the peer-reviewed journal, Structural Heart.

The findings and clinical meaningfulness assessments are reported by interventional and cardiovascular surgeons in the article, “Endovascular Baroreflex Amplification With the MobiusHD Device in Patients With Heart Failure and Reduced Ejection Fraction: Interim Analysis of the First-in-Human Results.”

Read The Article

A Feasibility Study Exploring the Effect of the MobiusHD Device in Patients with Heart Failure

Study Design

  • Prospective, open-label clinical trial
  • Subjects to be seen at the following intervals: 
    1 week, 1, 3, 6, 12, 18, and 24 months

Key Eligibility Criteria

  • Suitable carotid artery anatomy
  • Stable Guideline Directed Medical Therapy (GDMT) LVEF ≤ 40%
  • NYHA Class III
  • 6MWD distance of 150 to 400m
  • NT-proBNP ≥ 400 pg/mL

Positive Initial HFrEF Findings

This clinical trial is designed to evaluate the safety and effectiveness of the MobiusHD device in patients suffering from heart failure with reduced ejection fraction.

Patients were successfully implanted with the MobiusHD device in pre-procedurally determined locations.

Quality of Life Scores

Progressive improvements in patient-reported health status scores using the Kansas City Cardiomyopathy Questionnaire (KCCQ) were found at 3, 6, and 12 months follow-up. An improvement of 16 points in the average KCCQ overall summary scores was found; this exceeds the minimum improvement of 5 points recognized as that required to show a clinically meaningful change.

6 Minute Walk Distance

The Six Minute Walk Distance (6MWD) is a standard measurement of exercise tolerance for heart failure patients. Progressive improvements in 6MWD were found for EVBA patients showing an average improvement of 98 meters in walk distance at 12 months follow-up, exceeding the minimum clinically meaningful change of 30 meters.

NYHA Class Change

All patients enrolled in the EVBA HF-FIH study were categorized as symptomatic NYHA (New York Heart Association) Class III as reported by their physicians. At 12 months follow-up, 14 of 21 (67%) patients were re-classified to a lower Class II category showing relief of many pre-procedural clinical symptoms.

%LVEF Improvement

Prior to treatment, study patients had an average %LVEF (left ventricular ejection fraction) of 34.9%. Following EVBA with the MobiusHD device and with maintained HF medication therapy, the average %LVEF was 40.4% at 12 months follow-up. These echocardiographic changes suggest reverse remodeling due to the EVBA treatment.

Reduction in NT-proBNP

Natriuretic peptide tests (NT-proBNP) provide an objective characterization of heart failure. Improvements indicated by reductions of 10-30% have been reported to be clinically meaningful changes. EVBA patients in this study showed a 28% reduction in the median of NT-proBNP from baseline to 12 months follow-up.

Clinical Trial Results

All patients were successfully implanted with the MobiusHD device in pre-procedurally determined locations

Initial evidence through 12 months FU shows favorable effects on cardiac function and clinical profile.

  • Improved quality of life (KCCQ OSS)

  • Increased exercise tolerance 6MWD

  • Improved NYHA class

  • Improved LVEF

  • Reduction in NT-proBNP

View Clinical Trial